Spinogenix reports top line outcomes from trial of therapy for Fragile X syndrome

US-based biopharmaceutical company Spinogenix has published top line outcomes from a Phase II trial of SPG601 for treating Fragile X syndrome (FXS), a genetic disorder linked to autism and intellectual disability, in adult male patients.